Our research demonstrates that GLT8D1 is upregulated in GC tissues, and higher expression levels indicate more advanced tumor stage and poorer prognosis, suggesting that it has the potential to be a novel biomarker for GC progression. Here, GLT8D1 is linked to neoplasm.